LAK细胞和IL—2治疗晚期肝癌十例

Treatment of advanced liver cancer by autologous and/or homologous LAK cells combined with human natural LL-2

Ten patients with advanced liver cancer, primary in 5 and metastatic in the other 5, were treated with lymphokine-activated killer cells, autologous (aLAK) and/or homologous (hLAK) combined with human natural IL-2. Each course of treatment lasted 10 days. For aLAK/IL-2 treatment, white cells were collected from the patients to be treated by a cell separator on Day 4 and after 3-day culture of the mononuclear cells in vitro in the presence of IL-2 (500 units/ml), the aLAK cells (1-2 x 10(9)) were transferred back to the patient on Day 7 via the hepatic artery by selective catheterization. IL-2 (20-30 x 10(4) units) was given i.v. daily on Days 1, 2, 8, 9 and 10. For hLAK/IL-2 treatment LAK cells from healthy donors (0.5-1 x 10(9)) were administered i.v. on Days 1, 4, and 7 and IL-2 (20-30 x 10(4) units) i.v. daily on Days 2, 3, 5, 6, 8, 9, 10. Patients with primary liver cancer were all treated with aLAL/IL-2, followed by hLAK/IL-2 in 3. Patients with metastatic cancer in the liver were either treated with hLAK/IL-2 alone or in combination with aLAK/IL-2. The results of the treatment as monitored by B ultrasonography, CT scan and digital selective angiography are as follows: CR in 2 (with metastatic liver cancer), PR in 4 (3 with primary and 1 with metastatic liver cancer), MR in 2 and no response in 2. On follow-up, 7 patients survived greater than 6 months and 1 (a complete responder) for greater than 12 months. Side effects were mild with transient fever up to 38.5 degrees C and general malaise.